Allergy Therapeutics Plc (AGY) Ord GBP0.01
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Allergy Therapeutics starts dosing peanut allergy vaccine candidate
27 March 2023 15:16
(Sharecast News) - Allergy Therapeutics, a UK-based biotechnology company specialising in allergy vaccines, announced the start of the first application of its 'VLP Peanut' vaccine candidate in...
-
Allergy Therapeutics confident in funding as results remain late
20 January 2023 12:33
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics said in an update on Friday that it expects first-half revenue of £39.9m, making for a decrease of 18% year-on-year.
-
Allergy Therapeutics pauses production at Freeman facility
4 October 2022 14:10
(Sharecast News) - Biotechnology company Allergy Therapeutics has "proactively paused" production at the Freeman facility, part of its Worthing manufacturing site, to accelerate ongoing site...
-
Allegy Therapeutics trades 'robustly' in tough year
15 July 2022 11:58
(Sharecast News) - Allergy Therapeutics updated the market on the financial year just ended on Friday, with the phase one 'Peanut PROTECT' trial, incorporating "ground-breaking" VLP...
-
Allergy Therapeutics reports positive results from field study
25 October 2021 10:45
(Sharecast News) - Biotechnology company Allergy Therapeutics announced positive top-line results from its exploratory field study 'G309' to evaluate the efficacy and safety of its short-course...
Company announcements Announcements
-
Update on funding and preliminary results
1 October 2024 07:00
Allergy Therapeutics
-
Progression of patient cohorts in PROTECT Trial
17 September 2024 07:00
Allergy Therapeutics
-
Update on funding
27 August 2024 07:00
Allergy Therapeutics
-
Trading update for the year ended 30 June 2024
22 July 2024 07:01
Allergy Therapeutics
-
Appointment of Nominated Adviser and Sole Broker
22 July 2024 07:00
Allergy Therapeutics
-
Launch of new Company Long Term Incentive Plan
4 July 2024 14:22
Allergy Therapeutics
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.